The complex regulation of different neurotransmitter systems by endocannabinoids might be responsible for the distinctive impact of endocannabinoids on different symptom domains (psychosis and cognitive) in psychosis.15 First, it has been proposed that increased anandamide measured in the acute phase of psychosis might be a regulatory response of the brain to activate neuroplasticity-related pathways.61 Consequently, FAAH activity and the potential consequence in anandamide levels might reflect an adaptive response that supports cognition in FEP and CHR groups. Here, FAAH is linked to psychotic disorder.